Quick Answer
Spironolactone is a potassium-sparing aldosterone antagonist used as an adjunct in congestive heart failure management. This guide covers mechanism, CHF dosing for dogs and cats, potassium monitoring, and the important feline-specific adverse effect of facial pruritus with excoriation.
Key Takeaways
- ✓Spironolactone blocks aldosterone, preventing sodium retention and cardiac fibrosis in CHF
- ✓Dogs: 2 mg/kg PO q12-24h as adjunct to furosemide + ACE inhibitor + pimobendan
- ✓Monitor potassium q2-4 weeks initially -- additive hyperkalemia risk with ACE inhibitor
- ✓Cats: unique facial pruritus with excoriation -- inform owners upfront; discontinue immediately if seen
- ✓QUEST trial supports use in canine mitral valve disease Stage C CHF
Mechanism of Action and Clinical Indications
Pharmacology Spironolactone competitively antagonizes aldosterone at mineralocorticoid receptors.
*Effects:*
- Blocks aldosterone-mediated sodium retention and potassium excretion
- Mild natriuresis with potassium retention
- Anti-fibrotic: counteracts aldosterone-driven myocardial remodeling
- Mild diuretic -- NOT a substitute for furosemide
Why Aldosterone Blockade Matters in CHF In CHF, chronic aldosterone elevation causes sodium/water retention, K+/Mg2+ depletion, myocardial fibrosis, and endothelial dysfunction.
"Aldosterone escape" occurs even with ACE inhibitors -- spironolactone directly blocks aldosterone effects.
Indications in Dogs
- CHF adjunct (Stage C/D): alongside furosemide + ACE inhibitor + pimobendan
- Mitral valve disease, dilated cardiomyopathy
- ACVIM 2019 guidelines: optional adjunct for refractory Stage C CHF
Indications in Cats (Limited)
- Cats have unique adverse effect risk (facial pruritus)
- Reserve for refractory CHF only
- Many cardiologists avoid in cats
Dosing Protocols and Electrolyte Monitoring
Dosing
| Species | Dose | Route | Frequency |
|---|---|---|---|
| Dog | 2 mg/kg | PO | q12-24h |
| Dog (refractory) | 1-4 mg/kg | PO | q12h |
| Cat (cautious use) | 1-2 mg/kg | PO | q24h |
- Give with food for improved bioavailability
- Onset: 2-4 days; maximum effect: 1-2 weeks
Standard Stage C CHF Protocol for Dogs
| Drug | Dose | Role |
|---|---|---|
| Furosemide | 2-4 mg/kg PO q12h | Primary diuretic |
| Enalapril or Benazepril | 0.5 mg/kg PO q12h | ACE inhibitor |
| Pimobendan (Vetmedin) | 0.25 mg/kg PO q12h | Inodilator |
| Spironolactone | 2 mg/kg PO q12-24h | Aldosterone blockade |
Monitoring Schedule
| Parameter | Frequency | Target |
|---|---|---|
| Serum potassium | q2-4 weeks initially, q3 months | 3.5-5.5 mEq/L |
| BUN, creatinine | Same schedule | Normal or stable |
| Resting respiratory rate | Daily at home | <30 breaths/min |
| Body weight | Weekly at home | Stable |
Hyperkalemia Risk
- ACE inhibitor + spironolactone both raise potassium
- K+ >5.5 mEq/L: reduce/discontinue spironolactone
- K+ >6.0 mEq/L: ECG immediately (peaked T waves)
Feline Facial Pruritus and Adverse Effects
Feline Facial Pruritus -- Unique and Important Adverse Effect Cats can develop intense facial pruritus with self-induced excoriation -- a unique reaction not seen in dogs.
*Clinical presentation:*
- Intense facial scratching starting days to 2-4 weeks after initiating spironolactone
- Excoriation of periocular and periauricular skin
- Ulceration, crusting, secondary bacterial infection possible
- Completely reversible upon drug discontinuation
*Mechanism:* Unknown; possibly related to spironolactone's progestogenic structural similarity.
*Management:*
- Discontinue spironolactone immediately if pruritus develops
- Do NOT restart -- reaction recurs
- Inform cat owners proactively before starting treatment
Other Adverse Effects (Both Species)
- GI upset: vomiting, anorexia -- give with food
- Hyperkalemia (per above)
- Azotemia from over-diuresis
- Gynecomastia (rare)
Contraindications
- Significant renal failure
- Hyperkalemia (K+ >5.5 mEq/L)
- Addison disease (already hyperkalemic)
Evidence Base
- QUEST trial (dogs with MVD): extended survival in Stage C CHF
- RALES trial (human): spironolactone reduced CHF mortality 30%
- ACVIM 2019: optional adjunct for canine Stage C CHF
Related Articles:
- [Diltiazem for Cats with HCM](/articles/diltiazem-cats)
- [Lymphoma Treatment in Dogs](/articles/lymphoma-dogs-treatment)
Frequently Asked Questions
What is spironolactone used for in heart failure?
Spironolactone blocks aldosterone receptors, preventing sodium retention, potassium loss, and cardiac fibrosis in CHF. It is used as an adjunct to furosemide, ACE inhibitor, and pimobendan in dogs with Stage C or D heart failure.
Can spironolactone be given to cats?
Yes, with caution. The critical concern is a unique feline reaction: intense facial pruritus with periocular/periauricular excoriation developing within days to weeks of starting treatment. Inform cat owners about this risk. Discontinue immediately if pruritus develops.
How often should bloodwork be checked on spironolactone and enalapril?
Check potassium and kidney values at 2-4 weeks after starting, then every 3 months once stable. The combination raises potassium -- target 3.5-5.5 mEq/L. Also monitor resting respiratory rate daily and body weight weekly.
What should I do if my cat scratches its face after starting spironolactone?
Stop the spironolactone immediately and contact your veterinarian. This is the classic feline facial pruritus adverse reaction. It resolves within days to weeks of discontinuation. Do not restart.
References
- Bernay F, et al. Efficacy of spironolactone in dogs with MVD (QUEST study). J Vet Intern Med. 2010;24(2):331-341.
- Oyama MA, et al. ACVIM consensus guidelines for canine CHF. J Vet Intern Med. 2019;33(3):1127-1140.